Watch RSMDF. Know when insiders buy.
One email the day a filing lands. Free.
RSMDF
RESMED INC
22.61
+0.00 +0.00%
USD · close Sep 25
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $3.3BP/E 2.2DIV YIELD 10.61%FCF YIELD 50.58%REV TTM $5.7B +9.9%NET INCOME $1.5B +8.8%NET CASH $1.1B52W 11.85 – 28.25SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2026 · Jun 30derived | $1.5B | +8.6% | 58.8% | $448.7M | $383.4M | +1.0% | 2.64 | $454.6M | $51.1M | $403.5M | Aug 13 |
| Q3 2026 · Mar 31 | $1.4B | +10.8% | 62.2% | $499.8M | $398.7M | +9.2% | 2.74 | $554.1M | $33.7M | $520.5M | May 1 |
| Q2 2026 · Dec 31 | $1.4B | +11.0% | 61.8% | $491.7M | $392.6M | +13.9% | 2.68 | $339.7M | $28.5M | $311.2M | May 1 |
| Q1 2026 · Sep 30 | $1.3B | +9.1% | 61.5% | $446.5M | $348.5M | +11.9% | 2.37 | $457.3M | $43M | $414.4M | May 1 |
| Q4 2025 · Jun 30derived | $1.3B | +10.2% | 60.8% | $454.5M | $379.7M | +29.9% | 2.58 | $538.8M | $30.6M | $508.2M | Aug 13 |
| Q3 2025 · Mar 31 | $1.3B | +7.9% | 59.3% | $426.3M | $365M | +21.5% | 2.48 | $578.7M | $20.8M | $557.9M | May 1 |
| Q2 2025 · Dec 31 | $1.3B | +10.3% | 58.6% | $417.2M | $344.6M | +65.0% | 2.34 | $308.6M | $20.6M | $288M | May 1 |
| Q1 2025 · Sep 30 | $1.2B | +11.1% | 58.6% | $387.3M | $311.4M | +41.9% | 2.11 | $325.5M | $17.8M | $307.7M | May 1 |
| Q4 2024 · Jun 30derived | $1.2B | — | 58.5% | $381.2M | $292.2M | — | 1.98 | $440.1M | $24.9M | $415.2M | Aug 13 |
| Q3 2024 · Mar 31 | $1.2B | — | 57.9% | $374.6M | $300.5M | — | 2.04 | $402M | $21.2M | $380.8M | Apr 24 |
| Q2 2024 · Dec 31 | $1.2B | — | 55.6% | $275.1M | $208.8M | — | 1.42 | $272.8M | $23.4M | $249.5M | Apr 24 |
| Q1 2024 · Sep 30 | $1.1B | — | 54.4% | $289M | $219.4M | — | 1.49 | $286.3M | $30M | $256.2M | Apr 24 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2026 · to Jun 30 | $5.7B | 61.1% | $1.9B | $1.5B | 26.9% | 10.43 | $1.8B | $156.3M | $1.6B | $700M | $349.7M |
| FY2025 · to Jun 30 | $5.1B | 59.4% | $1.7B | $1.4B | 27.2% | 9.51 | $1.8B | $89.9M | $1.7B | $300M | $310.9M |
| FY2024 · to Jun 30 | $4.7B | 56.7% | $1.3B | $1B | 21.8% | 6.92 | $1.4B | $99.5M | $1.3B | $150M | $282.3M |
| FY2023 · to Jun 30 | $4.2B | 55.8% | $1.1B | $897.6M | 21.3% | 6.09 | $693.3M | $119.7M | $573.6M | $0 | $258.3M |
| FY2022 · to Jun 30 | $3.6B | 56.6% | $1B | $779.4M | 21.8% | 5.30 | $351.1M | $134.8M | $216.3M | $0 | $245.3M |
| FY2021 · to Jun 30 | $3.2B | 57.5% | $903.7M | $474.5M | 14.8% | 3.24 | $736.7M | $102.7M | $634M | — | $226.7M |
Every number comes from RESMED INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.